Small molecular glucokinase activators: has another new anti-diabetic therapeutic lost favour?
UNLABELLED: Glucokinase activators (GKAs) represent one of the leading hopes for the next generation of type 2 diabetes (T2D) therapeutics, showing efficacy in reducing blood glucose and HbA1c levels in animal models of T2D and short-term human trials. While the hypoglycaemic risks of GCK activation...
প্রধান লেখক: | , |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
2013
|